DiaMedica, Inc. (OTCQB: DMCAF) is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. It is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases. For more information, visit the company’s website at www.diamedica.com.